| Code | CSB-RA004888MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tafasitamab-Cxix, targeting CD19, a transmembrane glycoprotein exclusively expressed on B cells throughout their development from pre-B cells to mature B lymphocytes. CD19 functions as a critical co-receptor in the B-cell receptor complex, modulating signal transduction thresholds and regulating B-cell activation, proliferation, and differentiation. This target plays a significant role in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia, and other non-Hodgkin lymphomas, where aberrant CD19 expression contributes to disease pathogenesis.
Tafasitamab-Cxix is a humanized IgG1 monoclonal antibody engineered with Fc modifications to enhance antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against CD19-positive malignant B cells. This biosimilar provides researchers with a valuable tool for investigating B-cell biology, exploring mechanisms of immune-mediated tumor cell depletion, studying therapeutic antibody function, and developing novel strategies for treating B-cell malignancies in preclinical models.
There are currently no reviews for this product.